Építés alatt – nem éles oldal
Belépés

NCT05374928Befejeződött

Human Epilepsy Project 3

Human Epilepsy Project 3: Newly Diagnosed Idiopathic Generalized Epilepsy

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 22.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try to explore the underlying biological drivers of treatment response, including novel realms of exploration such as impact of the microbiome, and genetics. The identification of biomarkers that predict the likelihood of disease response would allow epilepsy patients to make more informed decisions about the factors affecting their quality of life, including plans for driving, relationships, pregnancy, schooling, work, and play. In addition to its impact on clinical care, the data and specimens collected in HEP3, including sequential electrophysiology, biochemical profiles and neuroimaging and banked DNA for future genomics studies, have the potential to provide new insights into the biological basis of IGE, thereby advancing the discovery of effective treatments and cures. By enrolling both newly diagnosed subjects (prognosis unknown) as well as subjects with established IGE who are already determined to be treatment resistant or treatment responsive, the study team can immediately test potential biomarkers in a confirmation cohort, which will accelerate identification of predictive biomarkers.

Állapot (regiszter)
Befejeződött
Vizsgálattípus
Megfigyeléses
Résztvevők száma
316 (tényleges)
Első benyújtás
2022. máj. 11.
Kezdés
2020. márc. 9.
Elsődleges befejezés
2025. dec. 31.
Fő szponzor
NYU Langone Health
Betegségek
Epilepszia
NCT-szám
NCT05374928

Mit vállalsz

  • Vizsgálat típusa: Megfigyeléses
  • Bevont résztvevők: 316
  • 2020. márc. 9. és az elsődleges befejezés (2025. dec. 31.) között
  • 18 helyszín, 2 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • History of previous or current significant psychiatric disorder that would interfere with study requirements
    • Cohort 2: Longstanding Treatment Responsive
  • History of previous or current significant psychiatric disorder that would interfere with study requirements
    • Cohort 3: Longstanding IGE, Treatment Resistant
  • History of previous or current significant psychiatric disorder that would interfere with study requirements
  • History of/suspicion of provoked seizures accounting for 25% or more of seizures over the prior 2 years (eg alcohol, non-adherence, significant sleep deprivation).

Más betegség

  • Focal epilepsy
  • Generalized/focal epilepsy mixed syndromes
  • Progressive neurological disorder (brain tumor, Alzheimer's disease, progressive myoclonic epilepsy, etc.)
  • Major medical co-morbidities (e.g. renal failure requiring dialysis, metastatic cancer, HIV, or significant liver or renal disease)
  • Autism Spectrum Disorder
  • History of chronic drug or alcohol abuse (misuse or excessive use that interferes with activities of daily living) within the last 2 years
  • Seizures only during pregnancy
  • Focal epilepsy
  • Paroxysmal nonepileptic seizures
  • Generalized/focal epilepsy mixed syndromes
  • Progressive neurological disorder (brain tumor, Alzheimer's disease, progressive myoclonic epilepsy, etc.)
  • Major medical co-morbidities (e.g. renal failure requiring dialysis, metastatic cancer, HIV, or significant liver or renal disease)
  • Autism Spectrum Disorder
  • History of chronic drug or alcohol abuse (misuse or excessive use that interferes with activities of daily living) within the last 2 years
  • Seizures only during pregnancy
  • Focal epilepsy
  • Paroxysmal nonepileptic seizures
  • Generalized/focal epilepsy mixed syndromes
  • Progressive neurological disorder (brain tumor, Alzheimer's disease, progressive myoclonic epilepsy, etc.)
  • Major medical co-morbidities (e.g. renal failure requiring dialysis, metastatic cancer, HIV, or significant liver or renal disease)
  • Autism Spectrum Disorder
  • History of chronic drug or alcohol abuse (misuse or excessive use that interferes with activities of daily living) within the last 2 years
  • Seizures only during pregnancy

Egyéb

  • Epileptic or developmental encephalopathy
  • Epileptic or developmental encephalopathy
  • Epileptic or developmental encephalopathy

Kiket keres a vizsgálat

  • Age ≥13 years at time of enrollment
  • Age ≥8 years at time of seizure onset
  • Clinical seizure(s) and history consistent with IGE. The only permitted seizure types are absence, myoclonus or generalized tonic-clonic convulsions
  • Occurrence of at least 1 seizure of any type in the 6 months prior to treatment
  • Patients must have one of the following:
    • GTCSs alone accompanied by generalized spike-wave consistent with IGE per adjudication review
    • GTCSs with a history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
    • GTCSs associated with a history of absence and/or myoclonus, not accompanied by generalized spike-wave consistent with IGE per adjudication review
    • A clear history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
  • Availability of a complete medication history since initiation of treatment, including doses and date of initiation
  • No competing cause of epilepsy (e.g. traumatic brain injury)
  • AED treatment (for seizures) instituted not more than 12 months before enrollment
  • Age ≥13 years at time of enrollment
  • Age ≥8 years at time of seizure onset
  • Clinical seizure(s) and history consistent with IGE. The only permitted seizure types are absence, myoclonus or generalized tonic-clonic convulsions
  • Patients must have had one of the following:
    • GTCSs alone accompanied by generalized spike-wave consistent with IGE per adjudication review
    • GTCSs with a history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
    • GTCSs associated with a history of absence and/or myoclonus, not accompanied by generalized spike-wave consistent with IGE per adjudication review
    • A clear history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
  • Availability of a complete medication history since initiation of treatment, including doses and date of initiation
  • No competing cause of epilepsy (e.g. traumatic brain injury)
  • Two years of well-controlled seizures.
    • No convulsive seizures in the last two years
    • Myoclonic or absence seizures must be rare (<2 per year) and non-disabling
    • Ongoing therapy with > 1 antiseizure medication
  • Age ≥13 years at time of enrollment
  • Age ≥8 years at time of seizure onset
  • Clinical seizure(s) and history consistent with IGE. The only permitted seizure types are absence, myoclonus or generalized tonic-clonic convulsions
  • Occurrence of at least 1 seizure of any type in the 6 months prior to treatment onset
  • Patients must have had one of the following:
    • GTCSs alone accompanied by generalized spike-wave consistent with IGE per adjudication review
    • GTCSs with a history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
    • GTCSs associated with a history of absence and/or myoclonus, not accompanied by generalized spike-wave consistent with IGE per adjudication review
    • A clear history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
  • Availability of a complete medication history since initiation of treatment. This should include doses and date of initiation if possible, but minimum information would include name of drug, approximate duration of administration and reason for discontinuation, if applicable.
  • No competing cause of epilepsy (e.g. traumatic brain injury)
  • Treatment resistant IGE
    • Initiation of treatment at least 2 years prior to enrollment
    • Treatment resistance, as defined by failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination to achieve seizure freedom). ASMs taken at enrollment would count towards this minimum.
    • Either or both of the following two:
    • One GTCC per year over the last 2 years. ii. Any type of seizure at least every 3 months which can consist of either: disabling myoclonus or absence (in the opinion of the subject and investigator) or GTCC d. Such seizures were not primarily due to significant illness (e.g, URI is not significant unless temperature >101oF (38.3oC), nonadherence to antiseizure medications or >2 alcoholic beverages within 48 hrs of seizure e. Ongoing therapy with > 1 antiseizure medication

A regiszterben nem jelölt feltételek

  • Cohort 1: Newly Diagnosed IGE

Életkor a regiszterben: 13 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (18)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Monash UniversityMelbourneAusztráliaIsmeretlen állapot
The Johns Hopkins HospitalBaltimoreEgyesült ÁllamokIsmeretlen állapot
Mid-Atlantic Epilepsy Sleep CenterBethesdaEgyesült ÁllamokIsmeretlen állapot
St Barnabas Medical CenterLivingstonEgyesült ÁllamokIsmeretlen állapot
University of MiamiMiamiEgyesült ÁllamokIsmeretlen állapot
Yale UniversityNew HavenEgyesült ÁllamokIsmeretlen állapot
NYU Langone Health - Comprehensive Epilepsy Center (CEC)New YorkEgyesült ÁllamokIsmeretlen állapot
Mount Sinai HospitalNew YorkEgyesült ÁllamokIsmeretlen állapot
Northwell HealthNew YorkEgyesült ÁllamokIsmeretlen állapot
University of PennsylvaniaPhiladelphiaEgyesült ÁllamokIsmeretlen állapot
Maine Medical CenterPortlandEgyesült ÁllamokIsmeretlen állapot
Mayo ClinicRochesterEgyesült ÁllamokIsmeretlen állapot
Minnesota Epilepsy GroupSaint PaulEgyesült ÁllamokIsmeretlen állapot
University of Utah HospitalSalt Lake CityEgyesült ÁllamokIsmeretlen állapot
University of Texas Health Science CenterSan AntonioEgyesült ÁllamokIsmeretlen állapot
University of California, San Francisco (UCSF)San FranciscoEgyesült ÁllamokIsmeretlen állapot
Washington UniversitySt LouisEgyesült ÁllamokIsmeretlen állapot
Georgetown UniversityWashington D.C.Egyesült ÁllamokIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.